← Leaderboards
Eric Collisson
University Of California, San Francisco
$14,159,893
Attributed
$21,147,568
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,147,568 · 10
By mechanism
R01$15,779,590 · 7
U24$4,212,474 · 1
K08$815,400 · 1
R21$340,104 · 1
Top collaborators
- Ajit Harishkumar Goenka5 shared
- David H Haussler5 shared
- Natalia Jura5 shared
- Adam R Renslo5 shared
- Zhen Jane Wang5 shared
- Jingchun Zhu5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Iwei Yeh$4,800,085
- Benjamin Huang$1,239,925
- Rama Soundararajan$690,000
- Jasmine Ching Ying Wong$730,345
- Avner Schlessinger$6,740,500
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsInnovationIn VivoResponseResistanceOncogenesPharmaceutical PreparationsSignal TransductionMalignant Neoplasm Of PancreasBaseTumorMutationKras2 GeneMouse ModelPancreatic Ductal AdenocarcinomaEventPlayGrantFosteringAutomobile DrivingPathway InteractionsCancer PatientGenomicsMalignant Neoplasm Of Lung
Grant awards (50)
Understanding efficacy and FE(II)-Promoted Activation of 1,2,4-Trioxolanes in cancer$660,920
R01 · FY2025 · CA · contact PI
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy$1
R01 · FY2025 · CA · contact PI
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy$702,342
R01 · FY2024 · CA · contact PI
Understanding efficacy and FE(II)-Promoted Activation of 1,2,4-Trioxolanes in cancer$655,693
R01 · FY2024 · CA · contact PI
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer$625,125
R01 · FY2023 · CA · contact PI
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy$598,284
R01 · FY2023 · CA · contact PI
The structural and functional basis of MET exon 14 activation and acquired drug resistance$220,129
R01 · FY2023 · CA
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations$188,364
R01 · FY2023 · CA · contact PI
The structural and functional basis of MET exon 14 activation and acquired drug resistance$182,223
R01 · FY2023 · CA · contact PI
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14$140,086
R01 · FY2023 · CA · contact PI
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer$626,596
R01 · FY2022 · CA · contact PI
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy$596,548
R01 · FY2022 · CA · contact PI
Genomics and Functional Characterization of NF1-mutated Lung Cancer$535,334
R01 · FY2022 · CA · contact PI
The structural and functional basis of MET exon 14 activation and acquired drug resistance$402,355
R01 · FY2022 · CA
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations$400,975
R01 · FY2022 · CA · contact PI
Tailoring Therapy to Pancreatic Cancer Subtypes$231,487
R01 · FY2022 · CA · contact PI
Tailoring Therapy to Pancreatic Cancer Subtypes$107,887
R01 · FY2022 · CA · contact PI
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy$624,558
R01 · FY2021 · CA · contact PI
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer$577,035
R01 · FY2021 · CA · contact PI
Genomics and Functional Characterization of NF1-mutated Lung Cancer$536,682
R01 · FY2021 · CA · contact PI
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations$412,108
R01 · FY2021 · CA · contact PI
The structural and functional basis of MET exon 14 activation and acquired drug resistance$410,565
R01 · FY2021 · CA
Tailoring Therapy to Pancreatic Cancer Subtypes$348,958
R01 · FY2021 · CA · contact PI
Visualization hub for genomics data exploration and translational discovery$860,716
U24 · FY2020 · CA
Genomics and Functional Characterization of NF1-mutated Lung Cancer$603,012
R01 · FY2020 · CA · contact PI
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations$445,066
R01 · FY2020 · CA · contact PI
The structural and functional basis of MET exon 14 activation and acquired drug resistance$409,930
R01 · FY2020 · CA
Tailoring Therapy to Pancreatic Cancer Subtypes$367,303
R01 · FY2020 · CA · contact PI
Visualization hub for genomics data exploration and translational discovery$723,803
U24 · FY2019 · CA
Genomics and Functional Characterization of NF1-mutated Lung Cancer$584,378
R01 · FY2019 · CA · contact PI
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations$432,955
R01 · FY2019 · CA · contact PI
The structural and functional basis of MET exon 14 activation and acquired drug resistance$408,060
R01 · FY2019 · CA
Tailoring Therapy to Pancreatic Cancer Subtypes$357,141
R01 · FY2019 · CA · contact PI
Visualization hub for genomics data exploration and translational discovery$867,939
U24 · FY2018 · CA
Genomics and Functional Characterization of NF1-mutated Lung Cancer$554,851
R01 · FY2018 · CA · contact PI
Tailoring Therapy to Pancreatic Cancer Subtypes$342,551
R01 · FY2018 · CA · contact PI
Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis$295,999
R01 · FY2018 · CA · contact PI
Visualization hub for genomics data exploration and translational discovery$870,973
U24 · FY2017 · CA
Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis$295,065
R01 · FY2017 · CA · contact PI
Visualization hub for genomics data exploration and translational discovery$889,043
U24 · FY2016 · CA
Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis$295,065
R01 · FY2016 · CA · contact PI
Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis$295,065
R01 · FY2015 · CA · contact PI
A Genetically Defined System to Identify Factors Essential for KRas Oncogenesis$180,286
R21 · FY2015 · CA · contact PI
Crucial Microenvironmental Cofactors for Pancreatic Cancer Pathogenesis$308,894
R01 · FY2014 · CA · contact PI
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma$163,080
K08 · FY2014 · CA · contact PI
A Genetically Defined System to Identify Factors Essential for KRas Oncogenesis$159,818
R21 · FY2014 · CA · contact PI
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma$163,080
K08 · FY2013 · CA · contact PI
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma$163,080
K08 · FY2012 · CA · contact PI
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma$163,080
K08 · FY2011 · CA · contact PI
A Model for Preclinical Biomarker Discovery in Pancreatic Ductal Adenocarcinoma$163,080
K08 · FY2010 · CA · contact PI